Dr. Clay, a Passionate Oncologist

What led to the Development of his Passion

Driven by the desire to overcome diseases and interest in medicine, Dr. Clay Siegal started seeking ways in which technology could be used to change the way people could regain hope of a healthy life. This included those with cancer, an area of interest since his studies in Zoology at the University of Maryland. He witnessed the brutal chemotherapy program that almost killed a patient who suffered from anemia rather than from cancer. He acquainted himself with other treatment methods and decided to come up with better methods.

Though making money was not a major influence, it was one of the determinants in the process. Dr. Clay notes that at Seattle Genetics, they make money through selling proprietary drugs such as FDA-approved antibody conjugates. Other way of making money include partnerships in production, and licensing of processes and technologies that Seattle Genetics have developed.

Dr. Clay explains that the reason for getting FDA approval is to make their drugs authentic, a fact that can help them make more profits. This is despite the long approval process. Seattle Genetics had to endure a tough time before becoming profitable but with a dynamic and energetic sales team, they have made it. The sales team have biotechnology knowledge on the products. Seattle Genetics uses a unique strategy of winning, dining, and negotiation as its marketing strategy.

Career and Education

Dr. Clay Siegal, Ph.D., is the CEO, and President of Seattle Genetics which he co-founded in 1998. The foundations were rigorous research, scientific innovation, and drug improvement practices. Previously, Dr. Clay worked at the National Institute of Health, National Cancer Institute, and Bristol-Myers Squibb. He was a member of the board of directors for various pharmaceuticals. Dr. Clay received the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year award.

He went to the University of Maryland for a Bachelor of Science in Zoology before receiving a Ph.D. in Genetics from George Washington University. Dr. Clay has 15 patents and has authored 70 publications. Dr. Siegall experience in cancer treatment and drug development research is over 20 years old.